|
|
|
Volumn 10, Issue 3, 2000, Pages 230-239
|
|
Update on the role of adjuvant interferon for high risk melanoma
|
|
Author keywords
Adjuvant therapy; Clinical trials; Interferon ; Melanoma
|
|
Indexed keywords
ALPHA INTERFERON;
ALPHA2A INTERFERON;
ALPHA2B INTERFERON;
ALPHA2C INTERFERON;
AMINO ACID;
BCG VACCINE;
BETA INTERFERON;
GAMMA INTERFERON;
GANGLIOSIDE GM1;
GANGLIOSIDE GM2;
GANGLIOSIDE GM3;
IMMUNOGLOBULIN G;
IMMUNOGLOBULIN M;
INTERFERON ANTIBODY;
MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;
MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;
NUCLEIC ACID;
RECOMBINANT ALPHA2B INTERFERON;
RECOMBINANT DNA;
CANCER ADJUVANT THERAPY;
CANCER PREVENTION;
CANCER RECURRENCE;
CANCER RISK;
CANCER STAGING;
CANCER SURVIVAL;
CLINICAL PROTOCOL;
CLINICAL STUDY;
CONTROLLED STUDY;
DOSE RESPONSE;
DRUG COST;
DRUG EFFICACY;
DRUG RESEARCH;
HUMAN;
INFORMATION PROCESSING;
LYMPH NODE METASTASIS;
MAXIMUM TOLERATED DOSE;
MEDICAL SOCIETY;
MELANOMA;
POSTOPERATIVE CARE;
PROGNOSIS;
REVIEW;
RISK ASSESSMENT;
SKIN ULCER;
THICKNESS;
UNITED STATES;
ANTINEOPLASTIC AGENTS;
CHEMOTHERAPY, ADJUVANT;
COMBINED MODALITY THERAPY;
COST-BENEFIT ANALYSIS;
DATA INTERPRETATION, STATISTICAL;
FOLLOW-UP STUDIES;
HUMANS;
INTERFERON ALFA-2B;
LYMPHATIC METASTASIS;
MELANOMA;
NEOPLASM RECURRENCE, LOCAL;
QUALITY OF LIFE;
RANDOMIZED CONTROLLED TRIALS;
REOPERATION;
RETROSPECTIVE STUDIES;
RISK FACTORS;
SKIN NEOPLASMS;
SURVIVAL ANALYSIS;
TIME FACTORS;
|
|
EID: 0034531435
PISSN: 11218142
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (21)
|
|
References (19)
|
